BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25594623)

  • 1. Recent advances in primary cutaneous T-cell lymphoma.
    DeSimone JA; Sodha P; Ignatova D; Dummer R; Cozzio A; Guenova E
    Curr Opin Oncol; 2015 Mar; 27(2):128-33. PubMed ID: 25594623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on treatment of cutaneous T-cell lymphoma.
    Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
    Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous T-cell lymphoma.
    Gemmill R
    Semin Oncol Nurs; 2006 May; 22(2):90-6. PubMed ID: 16720231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous T cell lymphoma: update on treatment.
    Wollina U
    Int J Dermatol; 2012 Sep; 51(9):1019-36. PubMed ID: 22909354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental treatment strategies in primary cutaneous T-cell lymphomas.
    Rozati S; Kim YH
    Curr Opin Oncol; 2016 Mar; 28(2):166-71. PubMed ID: 26844985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current management strategies for cutaneous T-cell lymphoma.
    Knobler E
    Clin Dermatol; 2004; 22(3):197-208. PubMed ID: 15262305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
    Paulli M; Berti E
    Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future directions for pentostatin (Nipent) usage in dermatology.
    Heald P
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs in cutaneous T-cell lymphomas.
    Scarisbrick JJ
    Curr Opin Oncol; 2016 Sep; 28(5):384-9. PubMed ID: 27390044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
    Sung JJ; Ververis K; Karagiannis TC
    J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous lymphomas: an update. Part 1: T-cell and natural killer/t-cell lymphomas and related conditions.
    Kempf W; Kazakov DV; Kerl K
    Am J Dermatopathol; 2014 Feb; 36(2):105-23. PubMed ID: 24556897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG
    J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.